Abstract: Disclosed are compounds of Formula I ##STR1## or pharmaceutically acceptable salts or solvates thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula I. Further disclosed is a method of treating allergy (for example asthma), inflammation, hypotension, raised intraocular pressure (such as glaucoma)--i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimer's, schizophrenia, obesity and migraine) comprising administering an effective amount of a compound of Formula I to a patient in need of such treatment.

Abstract: Hypocholesterolemic sugar-substituted 2-azetidinones are disclosed, as well as a method of lowering cholesterol by administering said compounds, pharmaceutical compositions containing them, and the combination of a sugar-substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.

Abstract: Substituted azetidinone hypocholesterolemic agents of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: Ar.sup.1 is aryl or R.sup.3 -substituted aryl;Ar.sup.2 is aryl or R.sup.4 -substituted aryl;R.sup.1 is selected from the group consisting of--(CH.sub.2).sub.q --, wherein q is 2, 3, 4, 5 or 6;--(CH.sub.2).sub.e --Z--(CH.sub.2).sub.r --, wherein Z is --O--, --C(O)--, phenylene, --NR.sup.10 -- or --S(O).sub.0-2 --, e is 0-5 and r is 0-5, provided that the sum of e and r is 1-6;--(C.sub.2 --C.sub.6 alkenylene)--; and--(CH.sub.2).sub.f --V--(CH.sub.2).sub.g --, wherein V is C.sub.3 -C.sub.6 cycloalkylene, f is 1-5 and g is 0-5, provided that the sum of f and g is 1-6;R.sup.2 is --(lower alkylene)--COR.sup.5 or --(CH.dbd.CH)--COR.sup.5 ;R.sup.3 and R.sup.4 are independently selected from the group consisting of 1-3 substituents independently selected from the group consisting of lower alkyl, --OR.sup.6, --O(CO)R.sup.6, --O(CO)OR.sup.9, --O(CH.sub.2).sub.1-5 OR.sup.6, --O(CO)NR.sup.6 R.

Abstract: 4-[(Heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinone hypocholesterolemic agents of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: A is optionally substituted heterocycloalkyl, heteroaryl, benzofused heterocycloalkyl, or benzofused heteroaryl;Ar.sup.1 and Ar.sup.2 are optionally substituted aryl;Q is a bond or, with the 3-position ring carbon of the azetidinone, forms a spiro group; andR.sup.1 is alkylene; alkylene wherein a carbon in the chain is replaced by --O--, --C(O)--, phenylene, --NR.sup.8 --, --S(O).sub.0-2 -- or cycloalkylene; or alkenylene; or, when Q is a bond, R.sup.1 can be alkylene substituted by one or two hydroxy groups or hydroxy derivatives, wherein the alkylene chain can optionally be joined to Ar.sup.1 through --O-- or --S(O).sub.0-2 -- or joined to the azetidinone ring through a --S(O).sub.